Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial

The Lancet

Volumn 378, Issue 9805, 2011, Pages 1779-1787

  Kappos, Ludwig ^a   Li, David ^b   Calabresi, Peter A ^c   O'Connor, Paul ^d   Bar Or, Amit ^e   Barkhof, Frederik ^f   Yin, Ming ^g   Leppert, David ^h   Glanzman, Robert ^h   Tinbergen, Jeroen ^h   Hauser, Stephen L ⁱ  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g GENENTECH INC   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; OCRELIZUMAB; PLACEBO;

ADULT; ARTICLE; CHILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HERPETIC STOMATITIS; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 81555202418     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61649-8     Document Type: Article

References (30)

1. J Furuzawa-Carballeda, MI Vargas-Rojas, AR Cabral Autoimmune inflammation from the Th17 perspective Autoimmun Rev 6 2007 169 175 (Pubitemid 46187336)
2. S Nessler, S Boretius, C Stadelmann et al. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage Brain 130 2007 2186 2198 (Pubitemid 47236612)
3. E Bettelli, D Baeten, A Jäger, RA Sobel, VK Kuchroo Myelin oligodendrocyte glycoprotein specific T and B-cells cooperate to induce a Devic-like disease in mice J Clin Invest 116 2006 2393 2402 (Pubitemid 44330138)
4. M Duddy, A Bar-Or B-cells in multiple sclerosis Int MS J 13 2006 84 90 (Pubitemid 44898369)
5. M Duddy, M Niino, F Adatia et al. Distinct effector cytokine profiles of memory and naive human B-cell subsets and implication in multiple sclerosis J Immunol 178 2007 6092 6099 (Pubitemid 46717389)
6. A Bar-Or, L Fawaz, B Fan et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67 2010 452 461
7. A Corcione, F Aloisi, B Serafini et al. B-cell differentiation in the CNS of patients with multiple sclerosis Autoimmun Rev 4 2005 549 554 (Pubitemid 41415768)
8. B Serafini, B Rosicarelli, R Magliozzi, E Stigliano, F Aloisi Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis Brain Pathol 14 2004 164 174 (Pubitemid 38656388)
9. M Hallek, K Fischer, G Fingerle-Rowson for the International Group of Investigators and the German Chronic Lymphocytic Leukaemia Study Group Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
10. SB Cohen, P Emery, MW Greenwald for the REFLEX Trial Group Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2006 2793 2806 (Pubitemid 44497758)
11. P Emery, R Fleischmann, A Filipowicz-Sosnowska for the DANCER Study Group The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum 54 2006 1390 1400
12. MC Genovese, JL Kaine, MB Lowenstein for the ACTION Study Group Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study Arthritis Rheum 58 2008 2652 2661
13. SL Hauser, E Waubant, DL Arnold for the HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 2008 676 688 (Pubitemid 351240747)
14. Ocrelizumab [data on file]. South San Francisco (CA): Genentech; 2003.
15. Morschhauser F, Marlton P, Vitolo U, et al. Interim results of a phase I/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed/refractory follicular non-Hodgkin's lymphoma. 49th ASH Annual Meeting and Exposition; Atlanta, GA; Dec 8-11, 2007. 645.
16. WI McDonald, A Compston, G Edan et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Ann Neurol 50 2001 121 127
17. JF Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452 (Pubitemid 14237132)
18. CP Genain, B Cannella, SL Hauser, CS Raine Identification of autoantibodies associated with myelin damage in multiple sclerosis Nat Med 5 1999 170 175 (Pubitemid 29068523)
19. E Meinl, M Krumbholz, R Hohlfeld B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation Ann Neurol 59 2006 880 892 (Pubitemid 43830920)
20. T Vallerskog, I Gunnarsson, M Widhe et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE Clin Immunol 122 2007 62 74 (Pubitemid 46026695)
21. AH Cross, JL Stark, J Lauber, MJ Ramsbottom, A Lyons Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients J Neuroimmunol 180 2006 63 70 (Pubitemid 44767709)
22. NL Monson, PD Cravens, EM Frohman, K Hawker, MK Racke Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis Arch Neurol 62 2005 258 264 (Pubitemid 40204747)
23. Emery P, Rigby W, Tak T, Dorner et al. Serious infections with ocrelizumab in rheumatoid arthritis: pooled results from double-blind periods of the ocrelizumab phase III ra program. American College of Rheumatology/ Association of Rheumatology Health Professionals 74th Annual Scientific Meeting; Atlanta, Georgia; Nov 6-11, 2010. 414.
24. JR Oksenberg, SE Baranzini, S Sawcer, SL Hauser The genetics of multiple sclerosis: SNPs to pathways to pathogenesis Nat Rev Genet 9 2008 516 526 (Pubitemid 351861542)
25. L Kappos, D Bates, G Edan et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Lancet Neurol 10 2011 745 758
26. JA Cohen, F Barkhof, G Comi for the TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
27. L Kappos, J Antel, G Comi for the FTY720 Study Group Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 2006 1124 1140 (Pubitemid 44394919)
28. L Kappos, EW Radue, P O'Connor for the FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
29. G Giovannoni, G Comi, S Cook for the CLARITY Study Group A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med 362 2010 416 426
30. The CAMMS223 Trial Investigators Alemtuzumab vs interferon beta-1a in early multiple sclerosis N Engl J Med 359 2008 1786 1801